Wednesday, March 31, 2004

Eidogen Licenses Software to Boehringer Ingelheim

Pasadena-based Eidogen announced that Boehringer Ingelheim is pilot licensing the company's computational drug discovery platform. Eidogen's software is targeted at structural informatics, which looks to combine bioinformatics and cheminformatics. The company's platform is designed to provide target prioritization, lead discovery, and lead optimization for drug discovery companies. Eidogen is backed by Tavistock Life Sciences. More information »

---